Neurotoxicity of antitumoral IL-2 therapy: evoked cognitive potentials and brain mapping.
Antitumoral interleukin-2 (IL-2) therapy is frequently associated with a neurotoxicity that manifests itself in neuropsychiatric disturbances and, more rarely, with neurological focal signs. With the aim of documenting the involvement of cognitive functions after IL-2 treatment, we studied 20 patients using evoked cognitive potentials (P300) and computer analysis of the EEG signal. A comparison of the tests performed before and after the subcutaneous infusion of IL-2 showed a significant lengthening in mean P300 latencies and a percentage increase in the EEG frequencies contained with the delta and theta bands, especially in the frontal regions.
Pace
A
A
Servizio di Neurologia, Istituto Regina Elena per lo Studio e la Cura di Tumori, Roma.
Pietrangeli
A
A
Bove
L
L
Rosselli
M
M
Lopez
M
M
Jandolo
B
B
D000328:Adult; D000368:Aged; D001921:Brain / Q000502:physiology*; D001931:Brain Mapping; D004569:Electroencephalography / Q000187:drug effects; D005074:Evoked Potentials, Visual / Q000187:drug effects*; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy; D009422:Nervous System Diseases / Q000139:chemically induced* / Q000503:physiopathology
D007376:Interleukin-2